Distribution · GCC · Announced 15 Oct 2026
ADCAN Pharma → Zulekha Medical Store
ADCAN Pharma has signed Zulekha Medical Store as its exclusive UAE sales and marketing partner — completing the commercial layer of a manufacturing platform that has now signed ten agreements in 2026.
Parties: ADCAN Pharma (United Arab Emirates) → Zulekha Medical Store (ZMS) (United Arab Emirates)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- United Arab Emirates
- Therapeutic area
- Cardiovascular
- Asset
- Exclusive sales and marketing partnership for ADCAN Pharma’s pharmaceutical portfolio in the UAE — combining ZMS’s distribution strength with ADCAN’s portfolio; supply chain delivery and patient access optimization
- Announced
- 15 Oct 2026
Our analysis
Why this matters
ADCAN added layer to its machine: go-to-market. Until now, every ADCAN deal built manufacturing depth — licensing in portfolios from five countries, biosimilars with MS Pharma, German registrations, Menarini batch release. This exclusive sales and marketing partnership with Zulekha Medical Store covers the commercial leg inside the UAE.
For CEOs: ADCAN is assembling a full-cycle pharmaceutical company in eighteen months — portfolio, manufacturing, regulatory, and now commercialization.
The full analysis is free to read with a work email on this page.